Sandoz, the generics and biosimilars business of Swiss pharma giant Novartis (NOVN: VX), has acquired rights to develop and commercialize Pfizer’s biosimilar of infliximab, PF-06438179, in the European Union.
Infliximab, the active ingredient of Merck & Co's blockbuster Remicade, is a tumor necrosis factor alpha inhibitor used to treat alpha inhibitor used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis.
The deal strengthens Novartis’ immunology portfolio which includes investigational biosimilars adalimumab, etanercept and rituximab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze